Skip to main content

Table 4 The association between BPE and tumor characteristics among women with breast cancer in the IMAGINE study

From: Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study

Premenopausal cases
Tumor characteristic Minimal/mild BPE Moderate/marked BPEa ORb 95% CI
Hormone receptor statusc
 Negative 48 (15%) 33 (16%) Reference  
 Positive 277 (85%) 178 (84%) 1.00 0.59–1.68
HER2
 Negative 277 (85%) 164 (78%) Reference  
 Positive 48 (15%) 47 (22%) 1.72 1.07–2.76
Histology
 Ductal 293 (90%) 194 (92%) Reference  
 Lobular/mixed/other 32 (10%) 17 (8%) 0.99 0.52–1.91
Stage
 Localized 220 (68%) 147 (70%) Reference  
 Regional 101 (31%) 60 (28%) 0.86 0.57–1.29
 Distant 4 (1%) 4 (2%) 1.45 0.34–6.21
Postmenopausal cases
Tumor characteristic Minimal BPE Mild/moderate/marked BPE ORb 95% CI
Hormone receptor status
 Negative 26 (27%) 30 (17%) Reference  
 Positivec 71 (73%) 145 (83%) 2.55 1.22–5.34
Human epidermal growth factor 2
 Negative 83 (86%) 152 (87%) Reference  
 Positive 14 (14%) 23 (13%) 0.89 0.37–2.13
Histology
 Ductal 80 (82%) 151 (86%) Reference  
 Lobular/mixed/other 17 (18%) 24 (14%) 0.65 0.30–1.43
Stage
 Localized 76 (78%) 132 (75%) Reference  
 Regional 19 (20%) 41 (23%) 0.75 0.36–1.53
 Distant 2 (2%) 2 (1%) 0.36 0.04–3.17
  1. Abbreviations: OR odds ratio, CI confidence interval, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor 2
  2. aEstimated for a single unaffected breast using BI-RADS (Breast Imaging - Reporting and Data System) guidelines by a single research radiologist blinded to case-control status, clinical characteristics, and medical history
  3. bMultivariable-adjusted odds ratio for BPE category estimated in logistic regression with additional adjustment for (heterogeneous/dense vs fatty/scattered); BMI (< 25, ≥25 and < 30, ≥ 30 kg/m2); and conditioned on matching criteria: race/ethnicity (non-Hispanic White vs other), recruitment site, and age at MRI (5-year categories)
  4. cConsidered positive if positive for estrogen or progesterone receptors